What Is Breakthrough Device Designation? A Practical Definition for Health Tech Leaders
Breakthrough Device Designation defined: an FDA status that speeds review of technologies addressing unmet needs for serious conditions.
Health technology runs on vocabulary, and few terms carry more weight in current strategy conversations than Breakthrough Device Designation. Here is what it means, why it matters, and the context every reader of our policy & regulation coverage should have.
The definition
Breakthrough Device Designation is an FDA status that speeds review of technologies addressing unmet needs for serious conditions. In practical terms, it has become a common milestone on the path to market for novel clinical AI.
Why it matters now
Consider the current numbers: the FDA-CMS TEMPO pilot ties regulatory evaluation to real-world outcomes and Medicare coverage, with Dexcom as its first participant (our coverage).
Meanwhile, the proposed CY2027 fee schedule would create Medicare's first payment category for clinical AI software (our coverage).
Where you'll see it in our coverage
The term appears throughout our Policy & Regulation reporting and the related topic feeds, where the companies, policies, and studies shaping it are tracked daily. When headlines reference Breakthrough Device Designation, this page is the grounding to read them with.
The bottom line
Watch the regulatory calendar: the rules being written this year will shape this market for the rest of the decade.